CAR-T cell therapy for the treatment of lung cancer: Current challenges and emerging therapeutic strategies

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Lung carcinoma is a leading cause of cancer mortality globally.
• Advanced non-small cell lung cancer (NSCLC) treatments like targeted therapy and immune checkpoint inhibitors (ICIs) face limitations due to recurrence and resistance.
• Chimeric antigen receptor (CAR) T cell therapy has shown success in blood cancers but faces challenges in solid tumors like NSCLC.

Purpose of the Study:

• To review the development of CAR-T cells for lung cancer, from preclinical research to clinical trials.
• To summarize tumor-associated antigens, ongoing clinical trials, and barriers to CAR-T cell therapy in lung cancer.
• To discuss strategies for enhancing CAR-T cell therapeutic efficacy in lung cancer.

Main Methods:

• Review of preclinical studies and ongoing clinical trials on CAR-T cell therapy for lung cancer.
• Analysis of biological barriers hindering CAR-T cell efficacy in solid tumors, including NSCLC.
• Synthesis of potential strategies to improve CAR-T cell therapy outcomes.

Main Results:

• CAR-T cell therapy development for lung cancer is progressing from early research to clinical evaluation.
• Key barriers include tumor antigen heterogeneity, on-target/off-tumor toxicity, immunosuppressive tumor microenvironment (TME), and T-cell dysfunction.
• Various strategies are being explored to enhance CAR-T cell function and persistence.

Conclusions:

• CAR-T cell therapy holds significant potential for treating lung cancer, despite existing biological hurdles.
• Overcoming barriers in antigen targeting, T-cell trafficking, and the TME is crucial for clinical success.
• Continued research and strategic development may establish CAR-T cells as a standard lung cancer treatment modality.